论文部分内容阅读
目的 观察依达拉奉联合舒血宁注射液辅治急性脑梗死的临床效果。方法 将60例急性脑梗死患者随机分为治疗组与对照组各30例。对照组应用常规治疗,而治疗组另加用依达拉奉和舒血宁注射液辅治,连用14d。观察2组临床疗效和治疗前后神经功能缺损(NIHSS)评分。结果 治疗组总有效率为93.3%高于对照组的70.0%,差异有统计学意义(P<0.05)。治疗前2组NIHSS评分差异无统计学意义(P>0.05),治疗后2组均低于治疗前,且治疗组低于对照组,差异均有统计学意义(P<0.05)。结论 依达拉奉联合舒血宁注射液辅治急性脑梗死,可显著改善脑梗死患者预后,疗效显著,值得临床推广应用。
Objective To observe the clinical effect of edaravone and shuxuening injection in the treatment of acute cerebral infarction. Methods Sixty patients with acute cerebral infarction were randomly divided into treatment group and control group with 30 cases each. The control group, conventional treatment, while the treatment group plus Edaravone and Shuxuening injection treatment, once every 14d. The clinical efficacy and NIHSS scores of two groups were observed before and after treatment. Results The total effective rate in the treatment group was 93.3%, which was significantly higher than that in the control group (70.0%, P <0.05). There was no significant difference in NIHSS score between the two groups before treatment (P> 0.05). After treatment, both groups were lower than before treatment, and the treatment group was lower than the control group, the difference was statistically significant (P <0.05). Conclusion Edaravone combined with Shuxuening injection in the treatment of acute cerebral infarction can significantly improve the prognosis of patients with cerebral infarction, the effect is significant, worthy of clinical application.